Abstract
The implementation of cardioprotective strategies involving pre-, intra-, and postoperative interventions is key during cardiac surgery requiring extracorporeal circulation (ECC). The primary goal of this study was to review the physiopathology and protection strategies against myocardial damage secondary to ECC during cardiac surgery. The administration halogenated anesthetics for cardiac anesthesia is common place due to their well-known cardioprotective effects and their capacity to ensure hypnosis. An optimal myocardial protection strategy requires that a comprehensive approach should be adopted to cover pre-, intra-, and post-operative interventions. Pre-conditioning and post-conditioning share numerous pathways, mainly based on mitochondrial signaling, antiapoptotic pathways, and reduced inflammatory mediators. However, volatile anesthetic can also be administered during ECC, in which mechanism of action has been scantly investigated, during this period and its biology is still unknown.
Keywords: Preconditioning, postconditioning, extracorporeal circulation, hypnotic agents, cardioprotection, cardiac surgery.
Current Vascular Pharmacology
Title:Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Volume: 16 Issue: 4
Author(s): M. Ramirez-Aliaga*, J.J. Escalona-Belmonte, A. Ramirez-Fernandez, M. Rubio-Navarro and J. Cruz-Manas
Affiliation:
- Department of Cardio-Anaesthesiology, University Hospital Virgen de la Victoria, Malaga,Spain
Keywords: Preconditioning, postconditioning, extracorporeal circulation, hypnotic agents, cardioprotection, cardiac surgery.
Abstract: The implementation of cardioprotective strategies involving pre-, intra-, and postoperative interventions is key during cardiac surgery requiring extracorporeal circulation (ECC). The primary goal of this study was to review the physiopathology and protection strategies against myocardial damage secondary to ECC during cardiac surgery. The administration halogenated anesthetics for cardiac anesthesia is common place due to their well-known cardioprotective effects and their capacity to ensure hypnosis. An optimal myocardial protection strategy requires that a comprehensive approach should be adopted to cover pre-, intra-, and post-operative interventions. Pre-conditioning and post-conditioning share numerous pathways, mainly based on mitochondrial signaling, antiapoptotic pathways, and reduced inflammatory mediators. However, volatile anesthetic can also be administered during ECC, in which mechanism of action has been scantly investigated, during this period and its biology is still unknown.
Export Options
About this article
Cite this article as:
Ramirez-Aliaga M. *, Escalona-Belmonte J.J. , Ramirez-Fernandez A., Rubio-Navarro M. and Cruz-Manas J. , Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery, Current Vascular Pharmacology 2018; 16 (4) . https://dx.doi.org/10.2174/1570161115666171116170806
DOI https://dx.doi.org/10.2174/1570161115666171116170806 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pyruvate Dehydrogenase Complex as a Target for Gene Therapy
Current Gene Therapy Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Current Algorithms for the Diagnosis of wide QRS Complex Tachycardias
Current Cardiology Reviews Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Growing Collateral Arteries On Demand
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging
Current Pharmaceutical Design Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
Current Topics in Medicinal Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Physiological Basis for Contractile Dysfunction in Heart Failure
Current Pharmaceutical Design Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets Realising Heart Regeneration
Current Tissue Engineering (Discontinued) Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Renoprotective Potency of Heme Oxygenase-1 Induction in Rat Renal Ischemia-Reperfusion
Inflammation & Allergy - Drug Targets (Discontinued) Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design